NCT03199612View on ClinicalTrials.gov

Sildenafil To Prevent Clot

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions
ThrombosisHemolysis
Interventions
DRUG

Sildenafil

To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.

DRUG

Placebo Oral Tablet

Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.

Trial Locations (1)

10467

Montefiore Medical Center, The Bronx

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Montefiore Medical Center

OTHER

NCT03199612 - Sildenafil To Prevent Clot | Biotech Hunter | Biotech Hunter